Evidence map›Paper›PMID 33554782›Full record

ArticleAmerican journal of physiology. Renal physiology2021

Mesenchymal stem cells protect renal tubular cells via TSG-6 regulating macrophage function and phenotype switching.

Yu Zhao, Xiang-Yang Zhu, Turun Song, Lei Zhang, Alfonso Eirin, Sabena Conley, Hui Tang, Ishran Saadiq, Kyra Jordan, Amir Lerman and 1 more

Open access · greenAbstract read
In one paragraph

Article in American journal of physiology. Renal physiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 2 countries.

Yu ZhaoDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0003-3295-7379
Xiang-Yang ZhuDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.
Turun SongDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.
Lei ZhangDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.
Alfonso EirinDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.
Sabena ConleyDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.
Hui TangDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.
Ishran SaadiqDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.
Kyra JordanDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.
Amir LermanDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
Lilach O LermanDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-3271-3887
Mayo Clinic · US

Funding

MSC-derived microvesicles in metabolic syndrome and renovascular diseaseR01DK102325 · NIDDK · MAYO CLINIC ROCHESTER · PI LERMAN, LILACH O · 2015 to 2018
$2.8M
Obesity-induced mesenchymal stem cell senescenceR01DK120292 · NIDDK · MAYO CLINIC ROCHESTER · PI LERMAN, LILACH O · 2019 to 2022
$2.6M
Quantitative magnetization transfer MRI for evaluation of renal fibrosisR01DK122734 · NIDDK · MAYO CLINIC ROCHESTER · PI LERMAN, LILACH O · 2020 to 2023
$2.2M
Noninvasive assessment of renal fibrosis using magnetization transfer MRIU01DK104273 · NIDDK · MAYO CLINIC ROCHESTER · PI LERMAN, LILACH O · 2014 to 2018
$1.8M
Noninvasive Evaluation of Renal Allograft Fibrosis by MRIR21AG062104 · NIA · MAYO CLINIC ROCHESTER · PI LERMAN, LILACH O · 2020 to 2021
$414k
HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) DK102325HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) DK104273HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) DK120292HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) DK122734HHS | NIH | National Institute on Aging (NIA) AG062104NIA NIH HHS R21 AG062104NIDDK NIH HHS R01 DK102325NIDDK NIH HHS R01 DK120292NIDDK NIH HHS R01 DK122734NIDDK NIH HHS U01 DK104273
6 · The paper itself

Abstract

Tumor necrosis factor (TNF)-α-induced gene/protein (TSG)-6 regulates the immunomodulatory properties of mesenchymal stem cells (MSCs), but its ability to protect the ischemic kidney is unknown. In a swine model of renal artery stenosis (RAS) and metabolic syndrome (MetS), we assessed the contribution of TSG-6 produced by MSCs to their immunomodulatory properties. Pigs were studied after 16 wk of diet-induced MetS and unilateral RAS and were either untreated or treated 4 wk earlier with intrarenal autologous adipose tissue-derived MSCs (

Indexed as

PhenotypeAnimalsCoculture TechniquesCytokinesEpithelial CellsHumansKidneyMacrophagesMesenchymal Stem CellsMetabolic SyndromeProtective AgentsRenal Artery ObstructionSwineTumor Necrosis Factor-alphaCytokinesProtective AgentsTumor Necrosis Factor-alphamacrophagemesenchymal stem cellsmetabolic syndromerenal artery stenosistumor necrosis factor-α-induced gene/protein-6

Identifiers

PMID33554782
PMCPMC7988807
OpenAlexW3129079293

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.